Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q4 FY26 Earnings Presentation
30 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, May 21, 2026
Slide 1: Exchange intimation letter for Investor Presentation Q4 FY26
21st May 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Pheroze Jeejeebhoy Tower, Bandra-Kurla Complex, Bandra (E), Dalal Street, Mumbai- 400 001 Mumbai - 400 051 Security Code: 524164 Security Symbol: IOLCP Subject: Investor Presentatio
Slide 2: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q4 & FY26
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q4 & FY26
Slide 3: Q4 & FY26 Performance
Q4 & FY26 Performance
Slide 4: Q4 & FY26 Standalone Performance Highlights
Q4 & FY26 Standalone Performance Highlights Q4 FY26 ₹ 619.5 Cr ₹ 53.2 Cr ₹ 94.3 Cr Revenue from Operations PAT EBITDA 17.4% YoY 39.8% YoY 68.2% YoY EBITDA Margin 15.2% PAT Margin 8.6% FY26 ₹ 2,319.1 Cr ₹ 290.4 Cr ₹ 137.7 Cr Revenue from Operations EBITDA PAT 11.5% YoY 29.3% YoY 36.4% YoY EBITDA Marg
Slide 5: Q4 & FY26 Standalone Performance Highlights
Q4 & FY26 Standalone Performance Highlights Pharmaceuticals Chemicals (Net of intersegment) Geographical Break-up (In ₹ Cr) (In ₹ Cr) 374.5 244.9 24% 1396.3 356.1 922.8 866.9 224.3 1212.3 322.3 205.5 172.3 62.2 76% 126.3 40.9 34.5 15.4 30.2 6.5 6.5 12.8 FY25 FY26 Q4 FY25 Q3 FY26 Q4 FY26 FY25 FY26 Q4
Slide 6: Standalone Profit & Loss Statement – Q4 & FY26
Standalone Profit & Loss Statement – Q4 & FY26 Particulars (in INR Cr.) Q4 FY26 Q4 FY25 Y-o-Y Q3 FY26 Q-o-Q FY26 FY5 Y-o-Y Revenue from Operations 619.5 527.8 17.4% 580.4 6.7% 2319.1 2079.2 11.5% Other Income 1.7 4.5 5.3 21.3 22.4 Total Revenue 621.2 532.3 16.7% 585.7 6.1% 2340.3 2101.6 11.4% Cost o
Slide 7: Standalone Balance Sheet- FY26
Standalone Balance Sheet- FY26 Particulars (in INR Cr.) Mar 26 Mar 25 Particulars (in INR Cr.) Mar 26 Mar 25 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1165.1 1158.0 (i) Equity share capital 58.7 58.7 (ii) Right to Use Asset 3.4 0.0 (ii) Other equity 17
Slide 8: Standalone Cash Flow Statement- FY26
Standalone Cash Flow Statement- FY26 Particulars (in INR Cr.) Mar 26 Mar 25 Cash Flow from Operating Activities Profit before Tax 184.4 137.9 Adjustment for Non-Operating Items 85.1 79.8 Operating Profit before Working Capital Changes 269.5 217.7 Changes in Working Capital -17.2 -20.7 Cash Generated
Slide 9: At a Glance
At a Glance
Slide 10: Journey So Far
Journey So Far 1986-91 1996-99 2000-07 2009-13 2015-16 2017-18 2019 - 20 2021-22 2023 2024 2025 2026 • 1986: • 2000 - Commencement • 2015 - USFDA, • 2019 - Unit-06 for • Paracetamol capacity • Commencement Incorporation of of Ibuprofen Unit-1 EIR for Ibuprofen Pantoprazole has been increased to of N
Slide 11: Business Overview
Business Overview Team size of 3000+ Largest producer of DSIR-approved R&D facility Over 20 products Major producer of Ethyl employees Ibuprofen and the only with 50+ scientists driving are commercialized Acetate in India with a company worldwide being innovation across APIs and with 9 products in c
Slide 12: Segment Overview- Pharmaceuticals
Segment Overview- Pharmaceuticals Largest global producer of Ibuprofen with complete Expanding non-Ibuprofen API segment with a A fully backward-integrated and automated facility backward integration, having an annual capacity of diversified portfolio across multiple therapeutic areas, for manufactu
Slide 13: Segment Overview- Specialty Chemicals
Segment Overview- Specialty Chemicals Manufacturing Acetic Asia’s first continuous dual REACH-certified for Ethyl Among the largest global Ethyl Acetate Anhydride with capacity of technology plant for MCA Acetate & Acetic Anhydride, manufacturers of Iso Butyl manufacturing capacity of 32,000 MTPA -
Slide 14: Pharmaceuticals- A Key Focus
Pharmaceuticals- A Key Focus Expanding the non-Ibuprofen Business Installed Capacity Regulatory Filings* Therapeutic Area USDMF, CEP & ANVISA GMP Metformin Hydrochloride 7200 MTPA Anti-Diabetic Approved, China DMF Active 59% 60% USDMF, CEP & ANVISA GMP 57% 58% Fenofibrate Multiproduct Plant Anti-Cho
Slide 15: Manufacturing Facilities
Manufacturing Facilities API manufactured in batch manner and intermediates Facility is coupled with ISO class-8 HVAC system, PSA Dedicated and multiproduct blocks involved in & Specialty chemicals in continuous product delivery Nitrogen & Purified water along with 185 MTPH steam manufacturing of AP
Slide 16: Research & Development
Research & Development From Lab to Launch: 20 Products Commercialized, 9 More in Pipeline — R&D at the Heart of Our Growth Story 3 14 21 Patents DMFs with USFDA CEPs with EDQM A 120-member highly Working on generic skilled team, including 50+ molecules with latest DSIR approved facility for In-house
Slide 17: Certifications & Accreditations
Certifications & Accreditations DMF Registration From ISO 9001:2015, 14001:2015 & USFDA Approved Facility EUGMP Certification EDQM Certificate of Suitability Halal Certified MFDS Korea 45001:2018 GMP certificate by Ministry of Industry and Trade of the Russian Federation GMP Certificate by Russian K
Slide 18: Core Management Team
Core Management Team Varinder Gupta | (Managing Director) Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence. Vikas Gupta | (Joint Managing
Slide 19: Board of Directors
Board of Directors Rajender Mohan Malla Sharad Tyagi Harpal Singh Ms Rajni Jha (Chairman and Independent (Independent Director) (Independent Director) (Independent Director) Director) o With four decades of experience held o Over 38 years of intrapreneurship in o Over 37 year's experience of banking
Slide 20: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Awarded EcoVadis Silver Medal recognizing strong ESG Performance & Global Sustainability Leadership; Ranks Among the Top 15% companies globally o Committed to becoming carbon neutral by 2050 o 100 % State of the art Zero liquid Discharge (ZLD)
Slide 21: Industry Overview
Industry Overview
Slide 22: API Industry- Overview
API Industry- Overview Global API Market Size (In USD Bn) Indian API Market Size (In USD Bn) 4.40% 368.98 38.60 8.10% North America holds over 38% of India is the 3rd largest API the API market in 2024. 245.59 producer globally, contributing 8% Asia-Pacific—led by India and to the market, with over
Slide 23: Specialty Chemicals Industry- Overview
Specialty Chemicals Industry- Overview Global Spec. Chem Market Size Indian Spec. Chem Market Size Region wise Spec. Chem Market Size Growth (FY25-30) (In USD Bn) (In USD Bn) 3.23% 11% 3.80% 1054.70 92.60 7% 780.30 64.50 4% 3 3% 3% 2% 2024 2033 2024 2034 North Latin Europe Middle Japan China India A
Slide 24: Historical Performance
Historical Performance
Slide 25: Historical Standalone Performance
Historical Standalone Performance Revenues EBITDA & EBITDA % Cash Profit After Tax 11.2% 12.1% 10.7% 12.4% 2243 2340 290 224 2163 2102 252 262 208 189 185 225 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Segmental Revenue Cash Flow from Operations (Net) Capex Spent 1396 290 257 1259 1
Slide 26: Summary Statement of Standalone Profit and Loss
Summary Statement of Standalone Profit and Loss Particulars (in INR Cr.) FY26 FY25 FY24 FY23 FY22 Revenue from Operations 2319.1 2079.2 2,132.8 2,217.1 2,184.0 Other Income 21.3 22.4 30.1 25.6 32.0 Total Revenue 2340.3 2101.6 2,162.9 2,242.7 2,216.1 Cost of Materials Consumed 1501.6 1358.3 1,435.1 1
Slide 27: Summary Statement of Standalone Balance Sheet
Summary Statement of Standalone Balance Sheet Particulars (in INR Cr.) Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Particulars (in INR Cr.) Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1165.1 1,158.0 921.1 750.5 559.5 (i) Equity
Slide 28: Summary Statement of Standalone Cashflow
Summary Statement of Standalone Cashflow Particulars (in INR Cr.) Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Cash Flow from Operating Activities Profit before Tax 184.4 137.9 182.6 189.5 222.8 Adjustment for Non-Operating Items 85.1 79.8 59.8 44.4 33.1 Operating Profit before Working Capital Changes 269.5 2
Slide 29: Way Forward
Way Forward Backward Integration for Margin Product Diversification Beyond Export Contribution to Rise Scaling Through Land Acquisition and Supply Chain Resilience Ibuprofen The non-Ibuprofen share in the pharmaceuticals segment has The company has purchased 101 The company adopts a strategic increa
Slide 30: Thank You
COMPANY : IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Mr. Abhay Raj Singh - Sr. VP & Company Secretary investor@iolcp.com E-mail: investor@iolcp.com www.iolcp.com www.iolcp.com INVESTOR RELATIONS ADVISORS : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a
IOL Chemicals and Pharmaceuticals — Q4 FY26 Earnings Presentation on 6ix